PTK 2015 Banner 
2015 Peptalk M Banner 

 

Cambridge Healthtech Institute’s
Membrane Proteins
A Valuable Resource and Target
January 21-22, 2015


Membrane proteins are the gateways to the cell and are valuable drug targets. For researchers to design better-targeted drugs, they need to know their structure and functional characteristics. However, determining these characteristics is difficult, because researchers need large amounts of membrane protein to characterize their functions and map their structures. Sources are scarce due to the practical problems of working with membrane proteins—specifically, difficulties in expression, purification and crystallization. Cambridge Healthtech Institute’s Membrane Proteins conference addresses the strategies and solutions for their extraction, expression and purification, and features case studies showcasing their value as an antibody drug target. Join the in-depth exploration of how to obtain functional membrane proteins, and learn more about this important protein class.

Preliminary Agenda 


Purification 

KEYNOTE PRESENTATION

The Distinct Issues of Membrane Proteins versus Soluble Proteins

Robert Stroud, Ph.D., Professor, Biochemistry/Biophysics and Pharmaceutical Chemistry, and Director, Membrane Protein Expression Center, University of California, San Francisco

Expression of Transmembrane Proteins in Yeast for Genetic, Biochemical and Structural Studies

Mark E. Dumont, Ph.D., Professor, Biochemistry and Biophysics, University of Rochester Medical Center

GPCR Purification: Protein Engineering and Process Optimisation Are Key Elements for Successful GPCR Crystallisation

Markus Koglin, Ph.D., Associate Director, Protein Engineering, Heptares Therapeutics

Strategies for Detergent Stabilization and Large-Scale Affinity Purification of the Functional G Protein-Coupled Receptors

Alexei Yeliseev, Ph.D., Staff Scientist, Group Leader, LMBB, NIAAA, National Institutes of Health

Overcoming Difficult to Express Proteins: Cell-Free Additives for Solubilizing and Characterizing Membrane Proteins

Matthew Coleman, Ph.D., Deputy Group Leader, Molecular Toxicology, Lawrence Livermore National Laboratory, and Senior Scientist, University of California, Davis


Expression and Production 

Designer Surfactant-Like Self-Assembling Peptides for Membrane Protein Purification and Stabilization

Sotirios Koutsopoulos, Ph.D., Research Scientist, Center for Biomedical Engineering, Massachusetts Institute of Technology

Production of Human Integral Membrane Proteins in Mammalian Cells

James D. Love, Ph.D., Director, Technology Development, Biochemistry, Albert Einstein College of Medicine

Life_TechnologiesAdvances for Maximizing Protein Yields in HEK293 and CHO Transient Expression

Henry C. Chiou, Ph.D., Associate Director, Life Science Solutions, Thermo Fisher Scientific


Discovery and Development of Antibody Targets 

GPCR Expression by Individual Cell Types: Novel Membrane Targets for Therapeutic Antibodies

Paul Insel, Ph.D., Professor, Pharmacology & Medicine, University of California, San Diego

Targeting T Cells with an Anti-Ion Channel Antibody with Ultralong CDR H3s

Vaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, The Scripps Research Institute

Molecular Snapshot of GPCR Regulation and Signaling by Arrestins: Emerging Avenues for Novel Drug Discovery

Arun Shukla, Ph.D., Professor, Medicine, Duke University Medical Center

Discovery and Optimization of Novel Functional Anti G-Protein Coupled Receptor Monoclonal Antibodies

Trevor Wilkinson, Ph.D., Associate Director, Protein Sciences, Antibody Discovery and Protein Engineering, MedImmune

High-Throughput Strategies to Obtain High Affinity, Specific, and Conformationally Selective Recombinant Antibodies to Membrane Proteins by Phage Display

Marcin Paduch, Ph.D., Technical Director, Synthetic Antibody & Crystallography Core Facility, The University of Chicago